<DOC>
	<DOCNO>NCT02644122</DOCNO>
	<brief_summary>The purpose study test good bad effect experimental drug call SF1126 . This drug test patient whose cancer control available standard therapy certain gene tumor . SF1126 drug inhibits cell protein call phosphatidyl inositol 3 kinase ( PI3K ) . PI3K part signal pathway tell cancer cell grow , survive , invade metastasize . PI3K also important role development blood vessel require support tumor growth . SF1126 develop SignalRx Pharmaceuticals , Inc . It consider experimental drug approve FDA disease treatment .</brief_summary>
	<brief_title>SF1126 Recurrent Progressive SCCHN Mutations PIK3CA Gene and/or PI-3 Kinase Pathway Genes</brief_title>
	<detailed_description>SignalRx Pharmaceuticals develop pan isoform specific PI-3 inhibitor call SF1126 treat patient advance metastatic cancer . SF1126 conjugate contains two component : SF1101 ( active drug ) SF1174 ( inactive tetrapeptide RGD target moiety ) Both component SF1126 play key role activity drug . SF1101 selective inhibitor certain member phosphatidyl inositol 3-kinase ( PI-3 ) family SF1174 bind selectively receptor know present neovasculature support tumor tumor cell . These component result drug design selective activity target delivery . This open label Phase II study SF1126 adult patient recurrent refractory advance SCCHN PIK3CA mutation . Treatment cycle ( 28 day ) consist SF1126 1110 mg/m2 administer intravenously ( IV ) twice per week ( separate least three day ) first four cycle weekly subsequent cycle .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<criteria>Diagnosis recurrent metastatic SCCHN site except lip , thyroid , salivary gland , nasopharynx . No known FDAapproved therapy available 's expect prolong survival great 3 month . Tumors least one follow know mutation PI3K signal pathway , via assay perform CLIAapproved setting ( Foundation Medicine FoundationOne test use . This assay use cutoff 5 % allele fraction mutation . Allele fraction request sample ) : 1 . PIK3CA , 2 . PIK3CG , 3 . PIK3R1 , PIK3R5 PIK3AP1 ( regulatory subunit ) , 4 . AKT mTOR , 5 . PTEN Note : PIK3CA amplification eligible . Prior receipt platinumcontaining chemotherapy recurrent/metastatic disease history progression disease within 6 month receive platinum part concurrent chemoradiation . Disease must amenable potentially curative treatment.. Has recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy . Myelosuppressive chemotherapy : At least 3 week since completion ( 6 week nitrosourea ) Biologic ( antineoplastic agent ) : At least 14 day since completion therapy biologic agent . Radiation ( XRT ) :1 week must elapse prior palliative XRT nontarget lesion . Adequate Bone Marrow Function Defined subject ( include status post SCT ) : Peripheral absolute neutrophil count ( ANC ) 1000/mm3 ; Note : must &gt; 7 day use hematopoietic growth factor 21 day pegfilgastrim Platelet count 75,000/ mm3 ( transfusion independent &gt; 7 day ) Hemoglobin 8.0 g/dL ( may receive transfusion ) Adequate Renal Function Defined As : Serum creatinine ≤ 1.5 x institution 's ULN ( upper limit normal ) , Creatinine clearance 50 ml/min Adequate Liver Pancreatic Function Defined As : Total bilirubin 1.5 x upper limit normal , ALT AST 5 x upper limit normal , Albumin 2 g/dL Adequate Central Nervous System Function Defined As : Subjects seizure disorder may enrol anticonvulsant seizures well control . Brain metastases spinal cord compression , unless treatment complete least 4 week study entry , stable without steroid treatment least 4 week . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac [ include life threaten arrhythmias ] , hepatic , renal disease ) . Unresolved toxicity ≥ CTCAE Grade 2 previous anticancer therapy except alopecia longterm radiation toxicity ( radiation relate toxicity 3 month great radiation exposure ) . Presence cardiac impairment define : Prior history cardiovascular disease include heart failure meet New York Hearth Association ( NYHA ) class III IV definition ; OR History myocardial infarction/active ischemic heart disease within one year study entry ; OR Uncontrolled dysrhythmias ; OR Poorly control angina . Participation trial investigational agent within prior 30 day . Pregnant breastfeeding female . History malignancy except curatively excise carcinoma situ cervix , nonmelanomatous skin carcinoma superficial bladder cancer solid tumor curatively treat evidence disease 3 year . Other case review possibly allow discuss approve Principal Investigator . Patients receive therapeutic dos warfarin . Blood pressure great 170/90 two standard deviation normal base age weight nomogram three separate measurement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>advanced cancer</keyword>
	<keyword>metastatic cancer</keyword>
	<keyword>Squamous Cell Carcinoma Head Neck</keyword>
	<keyword>SCCHN</keyword>
	<keyword>gene mutation</keyword>
	<keyword>PIK3R1 , PIK3R5 PIK3AP1</keyword>
	<keyword>PIK3CG</keyword>
	<keyword>AKT mTOR</keyword>
	<keyword>PIK3CA gene</keyword>
	<keyword>PI-3 kinase inhibitor</keyword>
	<keyword>PI-3 kinase pathway gene</keyword>
</DOC>